Date: 21 September 2026
The U.S. FDA has updated its regulations to support the use of innovative alternatives to traditional animal testing in the development of human drugs and biological products.
Key Highlights
- FDA is replacing references to “animal tests/studies” with broader terms such as “nonclinical tests/studies.”
- The updated framework recognizes scientifically appropriate New Approach Methodologies (NAMs).
- NAMs may include human-cell-based models, organ-on-chip technologies and computational approaches.
- The rule does not prohibit animal studies or mandate the use of alternative methods.
- FDA has also launched a database highlighting examples of NAMs considered or used in regulatory contexts.
Intelligence Perspective
This development may provide pharmaceutical and biotechnology companies with greater flexibility in nonclinical development strategies and encourage investment in human-relevant testing technologies.